The survey was sponsored by CSL Behring, which markets Berinert® (C1 inhibitor [C1-INH]), one of the three HAE therapies currently indicated for self-administration.
Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered, plasma-derived intravenous therapy, treats acute attacks of facial, abdominal and laryngeal hereditary angioedema (HAE) symptoms by providing C1 Esterase Inhibitor deficient adult and adolescent patients with the missing human protein. The safety and efficacy of Berinert in preventing HAE attacks have not been established.
Without C1 Esterase Inhibitor, people with HAE suffer from recurrent episodes of rapid swelling of areas of the skin and underlying tissues, including the face, mouth, throat and abdomen. CSL Behring has marketed its pasteurized and nanofiltered C1 Esterase Inhibitor concentrate, Berinert, in Germany for more than 30 years. The product is also approved and marketed in 23 other European countries, the United States, Australia, Canada, Israel, Argentina, Japan and South Korea.
Berinert is contraindicated in individuals with a history of life-threatening systemic reactions to C1 Esterase Inhibitor preparations, including anaphylaxis. The most serious adverse reaction reported in subjects who received Berinert in clinical studies was an increase in the severity of pain associated with HAE. In placebo-controlled clinical trial, dysgeusia was the most common adverse reaction r
|SOURCE CSL Behring|
Copyright©2012 PR Newswire.
All rights reserved